ArticleMedicine2025
Integrative bioinformatics analysis for identifying the mitochondrial-related gene associated with immune infiltration in sarcopenia.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The increasing prevalence of sarcopenia (SAR) has raised significant concerns in healthcare. Although mitochondrial dysfunction and immune disorders are recognized as risk factors, the interactions between them remain unclear. This study aims to identify potential diagnostic biomarkers associated with both phenotypes in the progression of SAR. Three transcriptional datasets were obtained from the GEO database. Gene set enrichment analysis (GSEA) was performed to explore the features of the training set, followed by filtering the differentially expressed genes (DEGs). Weighted gene co-expression network analysis was applied to select gene modules closely related to SAR. SAR-mitochondria-related DEGs were then determined by intersecting the DEGs, weighted gene co-expression network analysis, and mitochondrial-related genes from the MitoCarta3.0 database. Hub genes were further explored using LASSO and random forest machine learning algorithms. The regulatory molecules of these hub genes were predicted using the NetworkAnalyst database. Subsequently, receiver operating characteristic analysis was performed and the immune infiltration was analyzed using the CIBERSORT algorithm. A SAR model was established in C2C12 cells using d-galactose, and RT-qPCR experiments were performed for further validation. Gene set enrichment analysis results revealed that the training set genes are mainly enriched in mitochondrial function and energy metabolism. Through the machine learning methods, 5 hub genes were screened out from 32 SAR-Mito DEGs, namely MTRF1L, MICU1, DHTKD1, ACADM, and FHIT. A total of 42 transcription factors and 10 miRNAs strongly associated with the hub genes were detected. These hub genes demonstrated solid diagnostic potential in both training and validation sets. Furthermore, immune infiltration analysis indicated a significant reduction in neutrophil levels in SAR patients. The downregulation of the hub genes in d-galactose-induced C2C12 cells was confirmed. Collectively, our findings identified 5 potential biomarkers for the diagnosis and therapy of SAR and emphasized the interaction between mitochondrial function and the immune response in the development of this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.